EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor α antibody

Maiko Ikenouchi, Hirokazu Fukui, Soichi Yagi, Akira Nogami, Koji Kaku, Toshiyuki Sato, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Tetsuya Takagawa, Toshihiko Tomita, Taku Kobayashi und 1 weitere

Intestinal Research · 31.10.2025 · 23 (4) · 464-474

DOI: 10.5217/ir.2024.00148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Intestinal Research, erschienen am 31.10.2025. Verfasst von Maiko Ikenouchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Faculty of Medicine, Hyogo Medical University, Hyogo, Japan. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Tofacitinib (TFB), filgotinib (FIL), and upadacitinib (UPA) are Janus kinase (JAK) inhibitors approved for moderate-to-severe ulcerative colitis (UC). The appropriate positioning of each JAK inhibitor in the treatment algorithm, however, is unclear. Furthermore, real-world efficacy of JAK inhibitors for patients with UC and prior anti-tumor necrosis factor α antibody (aTNF) treatment are not fully investigated. We compared the efficacy and safety of 3 JAK inhibitors in patients with UC, considering their prior aTNF exposure.

Methods

A retrospective study was conducted in patients with UC who started TFB, FIL, or UPA at 2 academic centers. This propensity score-matched cohort study assessed the effectiveness of the 3 JAK inhibitors for UC in patients with and without prior aTNF exposure, comparing steroid-free clinical remission and response rates after 8 weeks.

Results

Among 274 patients who met the inclusion criteria, 145 experienced aTNF exposure (TFB: 59.2%, 100/169; FIL: 34.5%, 20/58; UPA: 53.2%, 25/47). Based on propensity score-matching, UPA led to a higher steroid-free clinical remission rates than TFB (adjusted odds ratio [aOR], 5.57; 95% confidence interval [CI], 1.42–21.90) or FIL (aOR, 9.00; 95% CI, 1.42–57.10) in patients exposed to aTNF. Steroid-free clinical remission and clinical response rates did not differ significantly between each group in patients non-exposed to aTNF. The incidence of adverse events was slightly higher with UPA than TFB or FIL.

Conclusions

UPA may be more effective for UC than TFB or FIL, especially in patients with previous aTNF exposure, although consideration should be given to adverse events.

Schlagwörter

Stichwörter der Autor:innen

FilgotinibJanus kinaseTofacitinibUlcerative colitisUpadacitinib

Autor:innen und Institutionen

  • Department of Gastroenterology, Faculty of Medicine, Hyogo Medical University, Hyogo, Japan.
  • Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
  • Center for Clinical Research and Education, Hyogo Medical University, Hyogo, Japan.

Zitieren

APA

Ikenouchi, M., Fukui, H., Yagi, S., Nogami, A., Kaku, K., Sato, T., Kawai, M., Kamikozuru, K., Yokoyama, Y., Takagawa, T., Tomita, T., Kobayashi, T., & Shinzaki, S. (2025). Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor α antibody. Intestinal Research, 23(4), 464-474. https://doi.org/10.5217/ir.2024.00148

Vancouver

Ikenouchi M, Fukui H, Yagi S, Nogami A, Kaku K, Sato T, et al. Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor α antibody. Intestinal Research. 2025;23(4):464-474. doi:10.5217/ir.2024.00148

BibTeX
@article{Ikenouchi2025,
  author = {Ikenouchi, Maiko and Fukui, Hirokazu and Yagi, Soichi and Nogami, Akira and Kaku, Koji and Sato, Toshiyuki and Kawai, Mikio and Kamikozuru, Koji and Yokoyama, Yoko and Takagawa, Tetsuya and Tomita, Toshihiko and Kobayashi, Taku and Shinzaki, Shinichiro},
  title = {Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor α antibody},
  journal = {Intestinal Research},
  year = {2025},
  volume = {23},
  number = {4},
  pages = {464--474},
  doi = {10.5217/ir.2024.00148}
}
Kostenlos starten →